Diabetes insipidus Medical Services in China

Diabetes insipidus (DI) is a rare endocrine disorder characterized by the inability to concentrate urine, leading to excessive production of dilute urine (polyuria) and intense thirst (polydipsia). Unlike diabetes mellitus, DI is not related to blood glucose dysregulation but rather stems from defects in the antidiuretic hormone (ADH), also known as vasopressin, pathway. There are four primary subtypes: central (neurogenic) DI, caused by deficient ADH synthesis or secretion due to hypothalamic or pituitary damage; nephrogenic DI, resulting from renal resistance to ADH due to genetic mutations (e.g., AVPR2 or AQP2 genes) or acquired causes such as chronic lithium use, hypercalcemia, or hypokalemia; gestational DI, a transient form linked to placental vasopressinase overexpression during pregnancy; and primary polydipsia (dipsogenic DI), driven by abnormal thirst regulation and excessive water intake that suppresses ADH release. Pathophysiologically, impaired ADH signaling disrupts aquaporin-2 water channel trafficking in the renal collecting ducts, preventing water reabsorption and causing persistent urinary water loss—often exceeding 3–20 L per day. Epidemiologically, DI affects approximately 1 in 25,000 to 1 in 50,000 individuals globally, with central DI accounting for ~75% of cases. Incidence peaks in adults aged 30–50 years, though congenital forms present in infancy. Risk factors include traumatic brain injury, neurosurgery (especially transsphenoidal procedures), autoimmune hypophysitis, infiltrative diseases (e.g., sarcoidosis, histiocytosis), pituitary tumors (e.g., craniopharyngioma), and long-term lithium therapy. Genetic forms—particularly X-linked nephrogenic DI—predominate in pediatric populations. Untreated DI significantly impairs quality of life: patients experience sleep disruption from nocturia, fatigue, cognitive fog, anxiety around fluid access, and social withdrawal. Chronic dehydration risks include electrolyte imbalances (notably hypernatremia), acute kidney injury, and, in vulnerable populations (e.g., elderly or cognitively impaired), delirium or seizures. Early diagnosis requires careful differentiation from psychogenic polydipsia and diabetes mellitus via serum sodium, plasma osmolality, urine osmolality, and formal water deprivation testing with desmopressin challenge. Misdiagnosis is common and delays appropriate management, underscoring the need for specialized endocrinology evaluation.

Diabetes insipidus (DI) is a rare endocrine disorder characterized by the inability to concentrate urine, resulting in polyuria (excessive urine output, often >3 L/day in adults), polydipsia (intense thirst), and risk of hypernatremia and dehydration. It arises from either deficient arginine vasopressin (AVP) secretion (central or neurogenic DI), renal resistance to AVP (nephrogenic DI), or less commonly, gestational or primary polydipsia. Accurate etiological differentiation—via water deprivation test, plasma/urine osmolality, serum sodium, and AVP measurement—is essential before initiating therapy. Management is tailored to the subtype and severity, with goals centered on maintaining euvolemia, normonatremia, and quality of life.

Conservative treatment forms the cornerstone of management, particularly in mild or transient cases and as adjunctive support across all subtypes. In central DI, patients are advised to maintain free access to water at all times; scheduled oral hydration (e.g., 15–20 mL/kg/day) helps prevent nocturnal dehydration and sleep disruption. Dietary sodium restriction (<2 g/day) reduces solute load and subsequent urine volume. Caffeine and alcohol intake must be minimized due to their diuretic effects. For nephrogenic DI, conservative strategies include high-fluid intake (often >4–5 L/day), low-sodium, low-protein diet (to reduce medullary solute gradient and glomerular filtration rate), and avoidance of NSAIDs if contraindicated. In infants and elderly patients, close monitoring of weight, skin turgor, capillary refill, and serum electrolytes is mandatory to detect early signs of volume depletion or hypernatremia. Behavioral counseling for primary polydipsia—including structured fluid intake schedules and cognitive-behavioral techniques—may reduce compulsive drinking.

Pharmacotherapy is indicated when conservative measures are insufficient. Desmopressin (DDAVP), a synthetic V2-receptor-selective AVP analog, is first-line for central DI. Available as intranasal spray, oral tablets, and sublingual melt, it has prolonged half-life (8–12 hours) and minimal pressor activity. Dosing is titrated to achieve urine output <2.5 L/day and serum sodium 135–145 mmol/L; typical adult doses range from 0.05–0.4 mcg twice daily. Overuse risks hyponatremia and water intoxication—thus, patients require education on dose adjustment during illness, fever, or reduced oral intake. For nephrogenic DI, thiazide diuretics (e.g., hydrochlorothiazide 12.5–25 mg/day) paradoxically reduce urine volume by inducing mild hypovolemia and enhancing proximal tubular reabsorption. Amiloride (5–10 mg/day) is frequently co-administered to prevent hypokalemia and counteract thiazide-induced upregulation of ENaC channels, which can worsen lithium-induced nephrogenic DI. In lithium-associated cases, reducing lithium dose or switching to alternatives (e.g., valproate) is prioritized. COX-2 inhibitors (e.g., celecoxib) may be considered off-label in refractory nephrogenic DI, though evidence remains limited. Intranasal or oral chlorpropamide (a sulfonylurea) is rarely used in partial central DI due to hypoglycemia risk and is not recommended in China per current NMPA guidelines.

Surgical intervention is reserved for specific etiologies of central DI. Transsphenoidal resection of pituitary adenomas, craniopharyngiomas, or Rathke’s cleft cysts may restore AVP synthesis if hypothalamic-pituitary axis integrity is preserved preoperatively. Similarly, decompression of hypothalamic compression from metastases or granulomatous lesions (e.g., sarcoidosis, histiocytosis) may improve AVP secretion. However, surgery carries inherent risks—including cerebrospinal fluid leak, meningitis, panhypopituitarism—and DI may persist or even worsen postoperatively. Therefore, surgical candidacy requires multidisciplinary evaluation by neuroendocrinology, neurosurgery, and neuroradiology teams. Radiotherapy is generally avoided in DI management due to delayed onset and potential for radiation-induced hypothalamic injury.

Treatment advantages in China reflect robust infrastructure, regulatory rigor, and integrated care models. The National Medical Products Administration (NMPA) has approved multiple high-bioavailability desmopressin formulations—including domestically manufactured sublingual melts and nasal sprays—with stringent batch consistency and stability testing. China’s tiered healthcare system enables seamless referral from community clinics to tertiary endocrine centers (e.g., Peking Union Medical College Hospital, Shanghai Jiao Tong University Affiliated Ruijin Hospital), where dynamic endocrine testing (e.g., hypertonic saline infusion test) and MRI pituitary protocols are standardized. Telemedicine platforms facilitate longitudinal monitoring of serum sodium and urine osmolality, especially in rural regions. Moreover, China’s national rare disease registry supports epidemiological research and accelerates clinical trial enrollment for novel therapies, including selective V2-receptor antagonists under investigation for nephrogenic DI. Cost-effectiveness is enhanced through inclusion of desmopressin and thiazides in the National Reimbursement Drug List, with out-of-pocket expenses reduced by >70% for insured patients.

Recovery and long-term management emphasize patient empowerment and prevention of complications. Patients should carry medical identification (e.g., wallet card stating 'Diabetes Insipidus – Requires Immediate Access to Water') and undergo annual endocrine review including pituitary hormone panel (ACTH, cortisol, TSH, IGF-1, gonadotropins), renal ultrasound, and bone mineral density assessment (particularly in chronic thiazide users). Education focuses on recognizing prodromal symptoms of hypernatremia (lethargy, confusion, muscle cramps) and hyponatremia (headache, nausea, seizures), with clear action plans for acute illness (e.g., temporary desmopressin hold during vomiting/diarrhea). Psychological support is integral: studies from Beijing Children’s Hospital report that >40% of pediatric DI patients experience anxiety related to nocturia and school-related fluid access limitations. Family members should be trained in emergency rehydration protocols and home sodium monitoring where available. Finally, women of childbearing age with central DI require preconception counseling, as pregnancy may alter desmopressin pharmacokinetics and increase risk of preeclampsia; close collaboration with maternal-fetal medicine specialists is advised. With comprehensive, individualized care, most patients achieve full functional recovery and normal life expectancy.